City of Hope shared a post on LinkedIn:
“A Phase 3 clinical trial shows promise for patients with KRAS G12C metastatic colorectal cancer no longer responding to chemotherapy.
Dr. Marwan Fakih published a study in the Journal of Clinical Oncology which found that combining sotorasib and panitumumab significantly prolongs survival compared to standard care. Over 30% of patients who received the higher dose saw their tumors reduced by more than half, versus just 1.9% with standard care.
The exciting results of this combination therapy suggest that it might become the new standard of care for this disease.
More posts featuring Colon Cancer.